Pyridazin-3(2H)-one Derivatives as Selective Inhibitors of Monoamine Oxidase-B Isoform (MAO-B)

Summary of the technology

This invention is concerned essentially with pyridazinone derivatives substituted at C4, C5 or C6 with dithiocarbamate fragments that are selective MAO-B inhibitors, and their use for the preparation of medicaments for treating disorders resulting from MAO-B hyperactivity, including neurodegenerative diseases, such as Parkinson´s and Alzheimer’s diseases and other dementias.
The pyridazine ring is a privileged fragment found in compounds with very different pharmacological properties, such as antihypertensive, antiplatelet, anti-inflammatory, antinociceptive, antidepressant, hypoglycemic, antiinfective or anticancer agents, many of them being pyridazin-3(2H)-one derivatives. The pyridazine ring is also included in polycyclic compounds acting as MAO-B inhibitors. However, simple pyridazin-3(2H)one derivatives have not been described so far as selective MAO-B inhibitors.
The present invention provides novel pyridazin-3(2H)-one derivatives substituted at C4, C5 or C6 with several dithiocarbamate moieties that selectively inhibit the MAO-B activity and whose structure is unrelated to those currently available.
Innovative aspects and advantages The novel pyridazin-3(2H)-one derivatives can be easily synthesized through a multicomponent reaction, in which the appropriate 6(5)(4)-bromoalkyl analogue, an amine and carbon disulfide react in the presence of anhydrous potassium phosphate at room temperature. The compounds of the present invention were inactive against MAO-A.
However, these simple pyridazinone derivatives are inhibitors MAO-B with IC50 values in the micromolar range.
Commercial applications and potential users The compounds of the present invention or their salts could be used by the pharmaceutical industry for the preparation of medicaments to treat disorders resulting from MAO-B hyperactivity, including neurodegenerative diseases, such as Parkinson´s and Alzheimer’s diseases and other dementias.

University of Vigo
University of Vigo

Type of collaboration

Licensing of the technology and collaboration on the commercialization of the product.

Inventors:

Mª del Carmen Terán Moldes, Pedro Besada Pereira, Tamara Costas Caamaño, Mª del Carmen Costas Lago, Noemí Vila Molares (Universidade de Vigo), Dolores Viña Castelao (Universidade de Santiago).

Intellectual property status

  • Granted Patent
  • Patent application number :Patent status : Spanish patent and PCT application.

Related Keywords

  • Pharmaceutics
  • Medicine, Human Health
  • Medical Research
  • Neurology, Brain Research
  • Pharmaceutical Products / Drugs
  • Medical/health
  • Pharmaceuticals/fine chemicals
  • Clinical Medicine
  • neurodegeneration
  • Parkinson’s disease
  • Pyridazin-3(2H)-one
  • dithiocarbamate
  • MAO-B
  • Alzheimer’s disease.

About University of Vigo

Public University

University of Vigo

Never miss an update from University of Vigo

Create your free account to connect with University of Vigo and thousands of other innovative organizations and professionals worldwide

University of Vigo

Send a request for information
to University of Vigo

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support